New DNA-based test approved to help verify blood compatibility

(HealthDay)—The U.S. Food and Drug Administration has approved the ID CORE XT DNA-based test to help doctors verify blood compatibility before a transfusion.

People who need repeated transfusions, such as those with sickle cell disease, are more likely to develop certain antibodies. If blood with poorly-matched antibodies is transfused, the procedure is more likely to lead to red-blood-cell destruction and a transfusion reaction, the agency explained.

“We know that DNA testing holds great promise—to provide more informative, accurate and cost-effective methods that can enhance patient care,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.

Traditionally, identifying red blood cell antigens requires use of a blood serum called antisera. This method has limitations, and the serum may be difficult to obtain, the FDA said.

Source: Read Full Article